Dr Reddy’s Laboratories shares gained almost one per cent on the BSE after the corporate introduced the launch of albendazole tablets within the US market. At 10:40 am, the shares of Dr. Reddy’s Laboratories had been buying and selling at Rs 5,143, increased by 0.82 per cent on the BSE.
Albendazole tablets are a therapeutic equal generic model of Albenza tablets, 200 mg, authorized by the U.S. Food and Drug Administration.
The Albenza model and generic had U.S. gross sales of about $27 million MAT for the twelve months ended November 2020.
The albendazole tablets can be found in 200 mg tablets in bottle depend sizes of two.
The Sensex was buying and selling at 49,427.75, decrease by 344.49 factors or 0.71 per cent and the NSE Nifty was at 14,807.90, down 84.10 ponts or 0.46 per cent on the time.